Member Info for Soupdragon78

Sorry chab, unless someone on the inside can answer then I don't know that, I guess it varies by how much needs doing by the patent lawyers.

It's part of the global patent process. Each national jurisdiction has to approve the patent. Its been approved in the US and Japan so far, still in the process for Europe (incl. UK) and also China.

Here's one for NFT's, the Japanese patent for NXP002 has now been granted as I said it would.

https://patentscope.wipo.int/search/en/detail.jsf?docId=JP344317072&_fid=US339759777

Thanks Troajan.

Not a trading share, the spread kills anyone trying to trade this, even when it was last up at 0.32 the sell price barely touched 0.27.

Its a case of wait for material news.

Thanks for your concern Mulder, whatever makes you feel better.

Thanks for your concern Mulder, whatever makes you feel better.

Thanks for you concern NFT's, whatever makes you feel better.

Indeed Mars.

I'm also pleased that NXP004 has come into play. I had thought that would sit on the back burner until after anything had been thrashed out with 002.

Nobody is locked in. Anyone here can sell quite easily, its a choice not to.

at least they've released the transcript of the last interview now. something to read over egg and chips.

https://www.***************************/nuformix-now-focusing-on-out-licencing-nxp002-nxp004-lonnfx/4121128409

ps. its on directors talk interviews dot com

That’s assuming we don’t get hit by an asteroid and life as we know it ceases to exist

Anyway, Avalyn’s phase 2b funding is irrelevant to NFX at this stage as Nuformix are in talks already for outlicence / partnering and won’t be going solo like Avalyn are doing.

By comparison, Avalyn are dosing at 100 milligrams, NXP002 was dosing at 100 micrograms and getting better results.

(There are 1000 micrograms in 1 milligram)

Good luck to Avalyn but they’re asking a lot of their patients.

The size of dose they require is massive, they are basically asking people to inhale a whole tablet twice a day to get average results.

“Participants were randomized to one of two treatment arms: 50 mg AP01 once daily (QD) or 100 mg twice daily (BID) delivered with the eFlow Nebulizer System“

Interestingly from Bristol-Myers phase 2 testing of their drug for PPF Progressive Pulmonary Fibrosis (less common than IPF), they trials 38% of patients in combination with either Esbriet or Ofev as standard of care, so could see its use as an add-on.

Indirectly this backs up NFX looking at nxp002 in combination with standard of care if the big boys are also looking at the same principle.

https://www.fiercebiotech.com/biotech/second-phase-2-win-bms-builds-case-first-class-contender-pulmonary-fibrosis

Yay! well done NFT's. Good to see your working and thank you.

Only things I would comment / add.

You'll need to add a guesstimate for the NXP001 payment they received last week (rns stated they had been paid immediately), my guesstimate is between 50k-100k for the immediate payment, so lets go with the low figure.

So lets say end of Sept 2023 cash position would be £600k

Post Sept year end.

There is a new near term payment from Oxilio, plus their payment at the end of phase 1 testing. So lets say £50k + £100k (as end of phase 1 is a milestone payment and on a par with previous)

Also remember there are warrants outstanding which when exercised will net £87.5k

So theres another circa £137k pending as income.

£600k less your deductions, I'm not 100% convinced on the £350k tests as the company are seeking a partnering deal which will cover this but will run with it..

£600k deduct costs of £510k leaves £90k cash witch income due of around £130k , so £220k cash or cash equivalents.

Show your workings please, then we'll chat.

Just to go back to July again NFT's, remember I posted my workings as to the cash position.

I asked you to present your workings as you say they don't have cash, but you still can't actually come up with anything to back up your argument? Any development on that front?

Maybe once you're chilled out you will read the paper I posted last night, that will help you understand the process thats happening at the moment.

The rat studies were successful in demonatrating tolerability, they had difficulty in consistent results for duration of action only. As the Boehringer paper outlines, this is common in IPF preclinial as rats are not the best medium to test on, they just happen to be the industry standard and majors are now moving away from that due to these issue.

NFX have subsequently proven duration of action which has closed out the question mark from early last year.

This was presented by Fibrofind at the recent IPF Summit.